Finance

Lists
GENB:NASDAQ
Generate Biomedicines Inc
$17.53
+8.75%
(+1.41) 1D
Aug 24, 2:20:54 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GENB...
Open
$16.67
High
$17.66
Low
$16.03
Mkt. cap
2.25B
Avg. vol.
559.44K
Volume
1.43M
52-wk high
$18.16
52-wk low
$11.00
No. of employees
312
Open
$16.67
High
$17.66
Low
$16.03
Mkt. cap
2.25B
Avg. vol.
559.44K
Volume
1.43M
52-wk high
$18.16
52-wk low
$11.00
No. of employees
312
News stories
From web sources and news partners
Profile
Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Somerville, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases. Wikipedia
About Generate Biomedicines Inc
CEO-
Employees312
Founded2018
HeadquartersSomerville, Massachusetts, United States
SectorBiotechnology
Websitegeneratebiomedicines.com
Analyst ratings
Based on 4 analysts giving stock ratings to GENB in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for GENB in the last 3 months.
Highest
Current $17.53
$30.00 (+71.14%)
Average
$25.25 (+44.04%)
Lowest
$22.00 (+25.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
$22.00
+25.5%
08/17/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$24.00
+36.9%
08/07/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+42.6%
08/07/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$30.00
+71.1%
06/24/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$26.00
+48.3%
04/09/2026
Eric Schmidt FCA
Cantor Fitzgerald
Buy
Initiated
-
-
03/24/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.52 / -$0.52
-0.64%miss
Revenue / Est. (USD)
6.31M / 4.20M
+50.21%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
8.82M
10.13M
7.22M
6.31M
Cost of goods sold
46.82M
59.74M
57.81M
64.33M
Cost of revenue
46.82M
59.74M
57.81M
64.33M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.15M
10.54M
13.52M
13.60M
Operating expense
10.15M
10.54M
13.52M
13.60M
Total operating expenses
56.97M
70.28M
71.34M
77.93M
Operating income
-48.15M
-60.15M
-64.11M
-71.61M
Other non operating income
-
-
-363.00K
-
EBT including unusual items
-44.26M
-56.70M
-61.69M
-67.20M
EBT excluding unusual items
-44.26M
-56.70M
-61.69M
-67.20M
Income tax expense
56.00K
44.00K
28.00K
53.00K
Effective tax rate
-0.13%
-0.08%
-0.05%
-0.08%
Other operating expenses
-
-
-
-
Net income
-41.68M
-52.43M
-61.45M
-67.26M
Net profit margin
-472.73%
-517.56%
-850.58%
-1,065.17%
Earnings per share
-
-
-1.07
-0.52
Interest and investment income
4.28M
3.79M
2.91M
4.63M
Interest expense
-368.00K
-307.00K
-182.00K
-155.00K
Net interest expenses
3.91M
3.48M
2.73M
4.47M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.84M
-54.73M
-63.04M
-66.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps